FDA Advises Biologics Firms to Assess and Control Subvisible Particles
This article was originally published in The Gold Sheet
Executive Summary
Be sure to monitor subvisible particles despite lack of standards, FDA says.
You may also be interested in...
FDA Focuses Latest Warnings on Accountability and Root Cause
Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.